|
English
|
正體中文
|
简体中文
|
Total items :2814936
|
|
Visitors :
27327514
Online Users :
1402
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
|
|
|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"ren m"
Showing items 1-11 of 11 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Pathogenesis-related protein 1 suppresses oomycete pathogen by targeting against AMPK kinase complex
|
Luo, X.;Tian, Tian T.;Feng, L.;Yang, X.;Li, Li L.;Tan, X.;Wu, Wu W.;Li, Z.;Treves, H.;Serneels, F.;Ng, I.-S.;Tanaka, K.;Ren, M. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study
|
Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2019-07-11T03:52:26Z |
Medium optimization for enhanced lipid production by chlorella protothecoides UTEX25
|
Ogden K.;Ren M.;Cheng K.-C.; Cheng K.-C.; Ren M.; Ogden K. |
| 臺大學術典藏 |
2019-07-11T03:52:26Z |
Medium optimization for enhanced lipid production by chlorella protothecoides UTEX25
|
Ogden K.;Ren M.;Cheng K.-C.; Cheng K.-C.; Ren M.; Ogden K. |
| 臺大學術典藏 |
2019-07-11T03:52:26Z |
Medium optimization for enhanced lipid production by Chlorella protothecoides UTEX25
|
Ren M.; Ogden K.; Cheng K.-C.; Ogden K.;Ren M.;Cheng K.-C. |
| 臺大學術典藏 |
2019-07-11T03:52:26Z |
Medium optimization for enhanced lipid production by Chlorella protothecoides UTEX25
|
Ren M.; Ogden K.; Cheng K.-C.; Ogden K.;Ren M.;Cheng K.-C. |
Showing items 1-11 of 11 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
